pharmaphorum
LightNews LightNews
banner
pharmaphorum.bsky.social
pharmaphorum
@pharmaphorum.bsky.social
130 followers 480 following 1.1K posts
pharmaphorum.com, and its magazine Deep Dive, is a leading online destination for pharmaceutical industry and healthcare news, insight, and debate
Posts Replies Media Videos
pharmaphorum.bsky.social
Fresh from its IPO at the end of last year, #InsilicoMedicine has added to its stable of partners after signing a new #alliance with #Servier that could be worth up to $888 million.

pharmaphorum.com/news/insilic...
Insilico adds Sanofi to partnership roster with $888m deal
Insilico has added to its partnerships list with an $888m cancer-focused alliance with Servier, just days after completing its long-awaited IPO.
pharmaphorum.com
January 5, 2026 at 1:23 PM
pharmaphorum.bsky.social
#GSK has claimed an important new approval for #Nucala in chronic obstructive pulmonary disease (#COPD), in #China, which is estimated to account for around a quarter of the #globalpatientpopulation.

pharmaphorum.com/news/china-c...
China clears GSK's Nucala for COPD
GSK has unlocked a big new market for Nucala for COPD - China - which accounts for around a quarter of the global patient population.
pharmaphorum.com
January 5, 2026 at 12:31 PM
pharmaphorum.bsky.social
#Sanofi could be months away from wider US approval for #Tzield, its first-in-class drug for delaying the progression of #type1diabetes (T1D), in #children as young as one.

pharmaphorum.com/news/sanofi-...
Sanofi seeks use of type 1 diabetes drug in younger kids
Sanofi could be months away from wider US approval for Tzield, its drug for delaying the progression of type 1 diabetes, in children as young as one.
pharmaphorum.com
January 5, 2026 at 11:10 AM
pharmaphorum.bsky.social
#NovoNordisk has wasted no time in launching its oral version of the weight loss drug #Wegovy in the US after its approval by the FDA, as 2025 drew to a close.

pharmaphorum.com/news/novo-no...
Novo Nordisk launches Wegovy pill at $149 a month
Novo Nordisk has followed through on its pledge for a swift launch of the Wegovy pill for weight loss, and revealed its pricing for self-payers.
pharmaphorum.com
January 5, 2026 at 10:33 AM
pharmaphorum.bsky.social
#NICE has said #Biogen's Tysabri can now be used by the #NHS in England and Wales to treat highly active relapsing-remitting #multiplesclerosis (MS), along with a lower-cost #biosimilar version of the drug.
NICE recommends wider use of Biogen MS drug via NHS
NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.
buff.ly
January 2, 2026 at 4:00 PM
pharmaphorum.bsky.social
#NovoNordisk has been handed a crucial legal win by #China's Supreme Court, which has upheld the company's #patent protection on #GLP1 agonist #semaglutide used for #diabetes and #weightloss.

pharmaphorum.com/news/china-d...
January 2, 2026 at 2:20 PM
pharmaphorum.bsky.social
As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to #CorceptTherapeutics with a decision not to approve #relacorilant, a drug for a rare #hormonaldisorder that causes #highbloodpressure.
FDA declines to approve Corcept's rare disorder drug
As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.
buff.ly
January 2, 2026 at 12:30 PM
pharmaphorum.bsky.social
Denmark's #Genmab has decided not to continue the development of a drug for #cancer, acasunlimab, which had reached phase 3 testing, after a #review of its medicines #pipeline.

pharmaphorum.com/news/genmab-...
January 2, 2026 at 11:21 AM
pharmaphorum.bsky.social
The FDA's usual end-of-year flurry of #regulatoryapprovals is a little lighter than usual, but the agency has delivered some end-of-year cheer to #VandaPharma after giving the go-ahead to its drug for #motionsickness.

pharmaphorum.com/news/vanda-e...
Vanda ends 40-year hiatus for new motion sickness drugs
The FDA has delivered some end-of-year cheer to Vanda Pharma after approving Nereus, its drug for the prevention of motion sickness.
pharmaphorum.com
January 2, 2026 at 11:01 AM
pharmaphorum.bsky.social
One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.
Insilico ends 2025 with $293m Hong Kong IPO
One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m
pharmaphorum.com
December 31, 2025 at 1:16 PM
pharmaphorum.bsky.social
Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives.
Ultragenyx, Mereo's brittle bone drug flames out in trials
Two phase 3 trials of Ultragenyx and Mereo's sclerostin inhibitor setrusumab in osteogenesis imperfecta missed their primary efficacy objectives
pharmaphorum.com
December 30, 2025 at 4:34 PM
pharmaphorum.bsky.social
A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January.
Judge blocks HHS' 340B rebate pilot at 11th hour
A federal judge in the US has granted a restraining order that will stop the 340B rebate model from launching as planned on 1st January
pharmaphorum.com
December 30, 2025 at 12:41 PM
pharmaphorum.bsky.social
J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.
J&J abandons trial of atopic dermatitis drug
J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal
pharmaphorum.com
December 29, 2025 at 6:14 PM
pharmaphorum.bsky.social
FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026. pharmaphorum.com/news/no-chri...
No Christmas present for Sanofi, as FDA turns down MS drug
FDA has turned down Sanofi's oral BTK inhibitor tolebrutinib for multiple sclerosis, despite suggesting earlier it would delay a decision until 2026
pharmaphorum.com
December 29, 2025 at 3:08 PM
pharmaphorum.bsky.social
More than 20 years after its approval, NICE has backed the use of bevacizumab as a treatment for colorectal cancer for the first time.
Biosimilars unlock use of bevacizumab in bowel cancer by NHS
More than 20 years after its approval, NICE has backed the use of bevacizumab as a treatment for colorectal cancer for the first time
pharmaphorum.com
December 29, 2025 at 2:49 PM
pharmaphorum.bsky.social
CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.
CMS aims for broader GLP-1 access via federal programmes
CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity
pharmaphorum.com
December 24, 2025 at 2:39 PM
pharmaphorum.bsky.social
Sanofi's last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5bn agreement to buy vaccine firm Dynavax.
Sanofi swoops on Dynavax with $2.5bn takeover deal
Sanofi's last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5bn agreement to buy vaccine firm Dynavax
pharmaphorum.com
December 24, 2025 at 1:54 PM
pharmaphorum.bsky.social
CMS unveils two more programmes in the Trump administration's efforts to cut drug prices, which have not been well received by the pharma industry.
Trump raises spectre of drug pricing mandates for Medicare
CMS unveils two more programmes in the Trump administration's efforts to cut drug prices, which have not been well received by the pharma industry
pharmaphorum.com
December 23, 2025 at 2:22 PM
pharmaphorum.bsky.social
The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.
Novo Nordisk gets FDA okay for Wegovy pill
The FDA has delivered a gift to Novo Nordisk ahead of the holiday season, with the prompt approval of its Wegovy pill.
pharmaphorum.com
December 23, 2025 at 2:21 PM
pharmaphorum.bsky.social
AstraZeneca will voluntarily take its #anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects. #pharmanews pharmaphorum.com/news/andexxa...
Andexxa reaches the end of the line in the US
AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects
pharmaphorum.com
December 22, 2025 at 3:44 PM
pharmaphorum.bsky.social
Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere. #pharmadeals #pharmanews
pharmaphorum.com/news/ipsen-l...
Ipsen licenses Simcere ADC in $1bn-plus deal
Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere
pharmaphorum.com
December 22, 2025 at 2:05 PM
pharmaphorum.bsky.social
AstraZeneca has had a setback in its #oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 #lungcancer trial. #pharmanews
pharmaphorum.com/news/azs-atr...
AZ's ATR inhibitor ceralasertib flunks lung cancer test
AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.
pharmaphorum.com
December 22, 2025 at 1:00 PM
pharmaphorum.bsky.social
Nine more #pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme. pharmaphorum.com/news/nine-mo... #pharmanews #marketaccess #lifesciences
Nine more companies sign pricing deals with Trump
Nine more pharma groups have agreed to lower the costs of medicines in the US under the Trump administration's most favoured nation (MFN) scheme
pharmaphorum.com
December 22, 2025 at 10:57 AM
pharmaphorum.bsky.social
BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market. pharmaphorum.com/news/biomari...
#BiotechDeals #MergersAndAcquisitions #LifeSciences #PharmaNews #BiotechBusiness
BioMarin ends year with $4.8bn play for Amicus
BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market
pharmaphorum.com
December 22, 2025 at 10:02 AM
pharmaphorum.bsky.social
The #BIOSECUREAct, now part of the National Defense Authorization Act (#NDAA), will put in motion #US government-wide restrictions on ‘#biotechnology companies of concern’ and eventually bar agencies from procuring their biotech equipment or services.

pharmaphorum.com/news/us-bios...
US BIOSECURE Act passed by Congress
The BIOSECURE Act, now part of the NDAA, will put in motion US government-wide restrictions on ‘biotechnology companies of concern'.
pharmaphorum.com
December 19, 2025 at 3:28 PM